Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome

Schizophrenia Research

Volumn 58, Issue 1, 2002, Pages 55-62

  Mahadik, Sahebarao P ^a,b   Khan, Mohammad M ^a   Evans, Denise R ^a,b   Parikh, Vinay V ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein D; Arachidonic acid; Essential fatty acids; First episode early psychosis; Lipid peroxidation; Membrane phospholipids; Oxidative stress; Schizophrenia

Indexed keywords

APOLIPOPROTEIN D; CLOZAPINE; ESSENTIAL FATTY ACID; POLYUNSATURATED FATTY ACID;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG EFFECT; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PSYCHIATRIC TREATMENT; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; APOLIPOPROTEINS; CLOZAPINE; COMPARATIVE STUDY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MIDDLE AGE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0036844447     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(01)00378-4     Document Type: Article

References (56)

1. Axelrod J. Receptor-mediated activation of phospholipase A2 and arachidonic release in signal transduction. Biochem. Soc. Trans. 8:1990;503-507.
2. Bloom F. Advancing neurodevelopmental origin of schizophrenia. Arch. Gen. Psychiatry. 50:1993;224-227.
3. Boyles J.K., Notterpek L.M., Wardell M.R., Rall S.C. Jr. Identification, characterization, and tissue distribution of apolipoprotein D in the rat. J. Lipid Res. 31:1990;2243-2256.
4. Coyle J.T., Putfarcken C. Oxidative stress, glutamate and neurodegenerative disorders. Science. 262:1993;689-695.
5. Essali M.A., Das R., de Belleroche J., Hirsch S.R. The platelet phosphoinositide system in schizophrenia: the effects of neuroleptic treatment. Biol. Psychiatry. 28:1990;478-487.
6. Evans D.R., Mahadik S.P., Akin J., Evans W., Jain D. Cell membrane essential fatty acid status in drug-naïve first-episode psychotic patients and its relation to outcome. Schizophr. Res. 49:2001;83.
7. Fenton W.S., Hibbeln J., Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol. Psychiatry. 47:2000;8-21.
8. Franz G., Reindl M., Patel S.C., Beer I., Unterrichter I., Berger T., Schmutzhard E., Poewe W., Kampfl A. Increased expression of apolipoprotein D following experimental traumatic brain injury. J. Neurochem. 73:1999;1615-1625.
9. Herken H., Uz E., Ozyurt H., Sogut S., Virit O., Akoyl O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatry. 6:2001;66-73.
10. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 30:1998;193-208.
11. Horrobin D.F. The effects of antipsychotic drugs on membrane phospholipids - a possible novel mechanism of action of clozapine. Peet M., Glen A.L., Horrobin D. Phospholipid Spectrum Disorders in Psychiatry. 1999;113-117 Marius Press, Lancashire, UK.
12. Horrobin D.F., Manku M.S., Hillman S., Glen I.A.M. Fatty acid levels in brains of schizophrenics and normal controls. Biol. Psychiatry. 30:1991;795-805.
13. Horrobin D.F., Glen A.I.M., Glen E.M.T., Skinner F. Red cell membrane fatty acids in schizophrenic patients with mainly positive or mainly negative symptoms. Schizophr. Res. 9:1993;221.
14. Hudson C.J., Young L.T., Li P.P., Warsh J.J. CNS signal transduction in the pathophysiology and pharmacology of affective disorders and schizophrenia. Synapse. 13:1993;278-293.
15. Jablensky A., Sartorius N., Ernberg G., Anker M., Korten A., Cooper J.T., Day R., Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. Psychol. Med. Monogr. (Suppl). 21:1991;1-97.
16. Kaiya H., Nishida A., Imai A., Nakashima S., Nozawa Y. Accumulation of diacylglycerol in platelet phosphoinositides turnover in schizophrenia: a biological marker of good prognosis. Biol. Psychiatry. 26:1989;669-676.
17. Kapur S., Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52:2001;503-517.
18. Keshavan M.S., Mallinger A.G., Pettegrew J.W., Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res. 49:1993;9-95.
19. Knipping G., Gogg-Fassolter G., Frohnwieser B., Krempler F., Kostner G.M., Malle E. Quantification of apolipoprotein D by an immunoassay with time-resolved fluorescence spectroscopy. J. Immunol. Methods. 202:1997;85-95.
20. Li M.X., Chlan-Fourney J., Juorio A.V., Bennett V.L., Shrikhande S., Keegan D.L., Oi J., Boulton A.A. Differential effects of olanzapine on the gene expression of superoxide dismutase and low affinity nerve growth factor receptor. J. Neurosci. Res. 56:1999;72-75.
21. Liu Z., Chang G.Q., Leibowitz S.F. Apolipoprotein D interacts with the long-form leptin receptor: a hypothalamic function in the control of energy homeostasis. FASEB J. 15:2001;1329-1331.
22. Mahadik S.P., Mukherjee S. Free radical pathology and the antioxidant defense in schizophrenia. Schizophr. Res. 19:1996;1-18.
23. Mahadik S.P., Mukherjee S., Correnti E., Kelkar H.S., Wakade C.G., Costa R.M., Scheffer R. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naïve patients at the onset of psychosis. Schizophr. Res. 3:1994;239-247.
24. Mahadik S.P., Mukherjee S., Horrobin D., Jenkins K., Correnti E.E., Scheffer R.E. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar and normal controls. Psychiatry Res. 63:1996;133-142.
25. Mahadik S.P., Mukherjee S., Correnti E.E., Scheffer R., Mahadik J. Elevated plasma lipid peroxides at the onset of non-affective psychosis. Biol. Psychiatry. 43:1998;674-679.
26. Mahadik S.P., Sitasawad V., Mulchandani M. Membrane peroxidation and the neuropathology of schizophrenia. Horrobin D., Glen A.L., Peet M. Phospholipid Spectrum Disorders in Psychiatric. 1999;99-111 Marius Press, Lancashire, UK.
27. Mahadik S.P., Evans D., Lal H. Oxidative stress and the role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 25:2001;463-493.
28. Mahadik S.P., Evans D.R., Terry A., Hill W.D. Neuroprotective action of atypical antipsychotics in schizophrenia: improved cognitive performance and underlying mechanism of action. Schizophr. Res. 49:2001;94.
29. Mahadik S.P., Evans D.R., Terry A., Hill W.D. Differential effects of risperidone and haloperidol on cognitive performance on rats and possible mechanism of action. Biol. Psychiatry. 49:2001;133S.
30. Morais-Cabral J.H.M., Atkins G.L., Sanchez L.M., Lopez-Boado Y.S., Lopez-Otin C., Sawyer L. Arachidonic acid binds to apolipoprotein D: implications for the protein's function. FEBS Lett. 366:1994;53-56.
31. Nasrallah H.A. Neurodevelopmental pathogenesis of schizophrenia. Psychiatr. Clin. North Am. 16:1993;269-280.
32. Neuringer M., Conner W.E., Lin D.S., Barstad L., Luck S. Biochemical and functional effects of prenatal and post-natal ω-3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc. Natl. Acad. Sci. U. S. A. 83:1986;4021-4025.
33. Ong W.Y., Lau C.P., Leong S.K., Kumar U., Suresh S., Patel S.C. Apolipoprotein D gene expression in the rat brain and light and electron microscopic immunocytochemistry of apolipoprotein D expression in the cerebellum of neonatal immature and adult rats. Neuroscience. 90:1999;913-922.
34. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 55:1995;998-1007.
35. Overall J.E., Gorham D.R. Brief psychiatric rating scale. Psychol. Rep. 10:1962;799-812.
36. Pettegrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kaplan D.B., Tretta M.G., Allen M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode drug-naïve schizophrenics. A pilot study of the dorsal prefrontal cortex using in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 48:1991;563-568.
37. Rassart E., Bedirian A., Carmo S.D., Guinard O., Sirois J., Terrisse L., Milne R. Apolipoprotein D: a review. Biochim. Biophys. Acta. 482:2000;185-198.
38. Reddy R., Yao J. Free radical pathology in schizophrenia: a review. Prostaglandins, Leukotrienes Essent. Fatty Acids. 55:1996;33-43.
39. Reddy R., Keshavan M.S., Yao J.K. Reduced polyunsaturated fatty acids in first-episode neuroleptic-naïve schizophrenia patients. Schizophr. Res. 49:2001;84.
40. Rotrosen J., Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;759-764 Raven Press, New York.
41. Sanchez L.M., Diez-Itza I., Vizoso F., Lopez-Otin C. Cholesterol and apolipoprotein D in gross cystic disease of the breast. Clin. Chem. 3:1992;695-698.
42. Simonion N.A., Coyle J.T. Oxidative stress in neurodegenerative disease. Annu. Rev. Pharmacol. Toxicol. 36:1996;82-106.
43. Simopoulos A.P. Omega-3 fatty acids in health and disease, and in growth and development. Am. J. Clin. Nutr. 54:1991;438-463.
44. Spreyer P., Schaal H., Kuhn G., Rothe T., Unterbeck A., Oleck K., Muller H.W. Regeneration-associated high levels expression of apolipoprotein D mRNA in endoneurial fibroblasts of peripheral nerve. EMBO J. 9:1990;2479-2484.
45. Stanley J.A., Williamson P.C., Drost D.J., Carr T.J., Rylett R.J., Malla A. An in vivo study of the prefrontal cortex of schizophrenic patients at different age of illness via phosphorous magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 52:1995;399-406.
46. Thomas E.A., Dean B., Pavey G., Sutcliffe J.G. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorder. Proc. Natl. Acad. Sci. U. S. A. 98:2001;4066-4071.
47. Thomas E.A., Danielson P.E., Nelson P.A., Priby T.M., Hilbush B.S., Hasel K.W., Sutcliffe J.G. Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. J. Neurochem. 76:2001;789-796.
48. Wainwright P.E. Do essential fatty acids play a role in brain and behavioral development? Neurosci. Biobehav. Rev. 16:1992;193-205.
49. Weinberger D.R. On the plausibility of the 'neurodevelopmental hypothesis' of schizophrenia. Neuropsychopharmacology. 14:1996;1S-11S.
50. WHO World Health Organization - The International Pilot Study of Schizophrenia. 1973;WHO, Geneva.
51. Yao J.K. Red blood cell and platelet fatty acid metabolism in schizophrenia. Horrobin D., Glen A.L., Peet M. Phospholipid Spectrum Disorders in Psychiatric. 1999;57-71 Marius Press, Lancashire, UK.
52. Yao J.K., Yasaei P., van Kammen D.P. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins, Leukotrienes Essent. Fatty Acids. 46:1992;39-46.
53. Yao J.K., van Kammen D.P., Welker J.A. Red cell membrane dynamics in schizophrenia: II. Fatty acid composition. Schizophr. Res. 13:1994;217-226.
54. Yao J.K., Reddy R., van Kammen D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J. Psychiatr. Res. 32:1998;385-391.
55. Yao J.K., Reddy R., van Kammen D.P. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 80:1998;29-39.
56. Yao J.K., Leonard S., Reddy R. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 42:2000;7-17.